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license (http://creativecommons.org/Summary Transitional medicine/science is shifting the medical research paradigm from
compound-based to evidence-based drug/device discovery. It is increasing interdisciplinary
collaborations, enhancing usage of advanced technologies, and facilitating therapeutics reach-
ing patients faster. The fundamental theme of evidence-based discovery is to apply what is re-
vealed in preclinical experimentation and to bring the resulting safety and efficacy to clinics.
In the medical fields, a contract research organization (CRO) works like a hired agent who has
corresponding knowledge and experience to conduct and complete tasks for a sponsor. The
relationship is business, and the contract is for deliverables. The increasingly high volume of
sponsored outsourcing work has made this for-profit business boom in the past decade. Loca-
tion boundaries are being blurred under globalization in the sciences and cross-border regula-
tory reviews. Getting from bench to bedside is a winding road with many obstacles and high
hurdles. Efficient teamwork becomes essential to materialize ideas and bring them to the mar-
ket. The professionals within team communities include drug/device makers and CROs. It has
become increasingly obvious that CROs play pivotal roles in the chain of discovery/design,
developing product to market through in vitro, in vivo, and ex vivo testing during preclinical
experimentations and clinical trials. Project management teams are responsible for nurturing
the materialization in a collaborative manner and enhancing the productivity of the pipelines.
CROs have many functional aspects and specialties, and no one organization is fully capable of
serving, i.e., integrated services, with expertise in each step of the chain to the needs of a
variety of sponsors. Instead of competition among the CROs themselves, the continuously ex-
panding market demands can be shared by Expertise-Based Integrated Services among allied
CROs, in contrast to the few large CROs. Empirically, the data generated from the chosen CROs
should meet the regulatory requirements for approval. A quality assurance unit from the
sponsor should be vigilant in performing audits and inspections of the candidate CROs prior
to contracting. Subsequently, close monitoring and well-organized project management guard
the path to the successful filing of the applications. A strategic alliance of translational med-
icine with CROs ensures proven therapeutics for disease treatment and prevention to be con-
nected with patient populations in a timely and cost-effective manner. The unbiased data
generated through CROs’ services can be used for a patient-driven approach in drug discoveryhai), Co., Ltd., Building 7, Lane 388, Jialilue Road, Pudong, Shanghai 201203, China.
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October, 2006.).and device control design. Thereafter, findings from the merged efforts can promote and com-
plete the feedback loop for refining existing medicines and exploring new medicines. A match-
making business may emerge and evolve from the procurement department of the inventor in
translational medicine and the business development sector of the CROs to generate a new
landscape in translational medicine.
Copyright ª 2015, The Author. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Paradigm shift
The course of a marketed drug/device after invention is
long, winding, and treacherous, and requires significant
monetary and intellectual investments. However, with the
possibility of detours occurring at every turn, pouring a
tremendous amount of time and manpower into this course
does not guarantee a successful application’s approval by
regulatory agencies. Vast research through chemical li-
braries and a meticulous synthesis of protein to discover
medicines have produced a large quantity of bioinformat-
ics. Meanwhile, new and refined synthetic biomaterials for
fabricating implantable devices have allowed much
improved biocompatibility in the past 2 decades. The fusion
between biologics and devices, such as drug-eluted stents
and nanotechnology in formulation, has reduced the clear
delineation of the two and increased their dependency on
each other. Demands from regulatory reviews, clinical
practices, and health care operations have pushed for
revelation on the mechanism of actions of medicines
because of safety concerns, accessibility, and economic
considerations. In addition, value generation is a key factor
for inventors to convince investors to continue their mon-
etary support, which consequentially models the critical
paths of choosing research and development (R&D)ine. The massive searches in tr
chemes. (Source: Adapted andprocesses and setting business milestones. Under these
circumstances, translational medicine emerges and there-
fore manifests the evolved evidence-based medicine [1e9].
Although the regulatory governed clinical trial phases
remain the common themes for invention, paradigm shift-
ing has occurred in the early stages of R&D, as illustrated in
Fig. 1.
Productivity and valuation are closely related. Mergers
and acquisitions (M&As) in the industry of medicine are
intended to boost productivity and ultimately attain top-
line growth [10]. Paradoxically, the evidence has shown
that industry consolidation results in less investment in
R&D. It is abundantly obvious that R&D outputs, if
measured by new medicine approvals, suffer substantially
from the reduced investment. Early-stage R&D suffers most
from this negative impact owing to the lengthy period
required to yield convincing data and the shift in monetary
support to clinical trials. It is the attrition of human re-
sources that has led M&As to create tremendous uprooting
in organization stability and in scientific continuity. Minute
but crucial pieces of information on know-how may be lost
during personnel transitions. The remaining staff may face
high hurdles in project management to move products in
the pipelines. Outsourcing becomes the eminent solution,
besides the ineffective cross-functional consortiumsaditional approaches have changed to targeted disease mech-
modified from: John J. Orloff, MD, Norvartis Pharma AG, 12
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to maintain productivity under these circumstances.
Contract research organizations
Prior to and in the early stages of the computer era, con-
tract research organizations (CROs) for pharmaceuticals
were utility companies doing large-volume throughputs,
conducting toxicology evaluations, and managing clinical
trials. They have evolved from the more sophisticated de-
mands of the short-handed medicine and device industries
to perform increasingly complex tasks, such as conducting
tests to reveal the pharmacokinetics and pharmacody-
namics and/or biocompatibility of implants under normal
physiology conditions and pharmacological efficacy and/or
tissue engineering repairs in targeted disease models.
The continental divide in CROs is preclinical and clinical.
The former consists of subdivisions largely grouped into
drug screening/design control, compound synthesis/device
manufacturing, toxicology/biocompatibility, and efficacy/
functional repair. The latter has operations in a flow of
phases in human trials to meet regulatory requirements.
Although the pharmaceutical industries prefer to hold on to
the intellectual properties, M&As and generic products
have blurred the delineations that have differentiated
companies from brands in the past. Medical industry ex-
ecutives have realized that a faster turnaround to their
investment in R&D may come from joint ventures with
similar-minded competitors. It is well known that unbiased
data should be generated by an independent third party to
convince corporate partners and regulatory bodies. The
fertile ground for CROs is therefore continuing to expand
and has become deeply involved in medical sciences, from
concept to commercial stages.
Collaboration between sponsors and CROs
There are several common business models for contracts
between the sponsor and the CRO. Traditional project-based
contracts take up a large portion of all contracts, although
increasingly, partnership Full Time Employee (FTE)-based
contracts have recently begun establishing a strong footing.
Strategic alliances with CROs can build trust and facilitate
more open and frequent communication on project details
and priorities, allowing teams to resolve issues from a di-
versity of business cultures and operational cores.
Criteria of choosing a CRO
Sponsors searching for a trustworthy CRO to conduct out-
sourced work look for corresponding technical competency,
quality, turnaround time, and cost. Technical competency
represents the capability to perform and experience in
conducting similar projects that facilitate the attainment
of product development goals. In the era of biosimilars and
510(k) products, familiarity with the targeted commercial
product sharply lowers the learning curve, reduces guess-
work, and avoids unnecessary failures. In addition, past
involvements in similar experiments will help to guide
through a swath of obstacles. Quality control and assuranceare the two cohesive fundamentals for regulatory filings.
They not only delineate good practice in all kinds of oper-
ations but also promote the credibility of the obtained
data. Satisfying performance in these areas guarantees a
smoother and quicker regulatory review process. Well-
managed project timelines are crucial to the product
development milestones for data collection, which in turn
pare overall costs. Aggressively planned Gantt charts
commonly cause widespread stress and human error.
Consensual logistics management can prepare and control
expectations during complex operations. Often, shortcuts
and seemingly direct routes increase the monetary invest-
ment necessary to patch up holes and/or increase the risk
of failure from haste. Commoditizing on contract prices is a
quality killer, as additional time and money may be needed
to recover from a botched experiment. Needless to say, the
impact of this is a major hindrance to the progress of
product development in the pipelines.Finding the match
Integrated services from a single CRO would be ideal, which
is almost a reproduction of the preexisting environment and
operational styles prior to reorganization in the inventor’s
facilities. It is obvious that this ideal condition bears the
pitfalls of the same in the old systems. Although larger CROs
may be able to recruit the best people in specific service
areas, the layers of communication involved can become
barriers to the smooth progression of discovery/design in
product development. The transformation of a scientist in
the inventor’s facilities to become a project manager should
focus on talent, intuition, motivation, and leadership. This
daunting task is like picking a field marshal from ranked
generals to lead. Instead, choosing multiple CROs, each of
which has its own focused specialties, may become an
excellent alternative. That is, programs can be coordinated
into a stream by a person with keen scientific instinct and
thorough personal communication skills, and make each
CRO’s study/technical director the fieldmarshal of a specific
segment while materializing the idea to the market.
The concept of Expertise-Based Integrated Service
(EBIS), which has been well received by the industry, can be
extended to serve virtual companies and academic spin-
offs. The allied EBIS CROs, as illustrated in Fig. 2, provide
for each of the segments to materialize the idea and bring
it to the market. This one-window shopping transaction
reduces the anxiety and difficulties attached to scientific
knowledge and experience gaps of the project manager/
coordinator in the inventor’s facilities and streamlines the
process to achieve the goals/milestones in a timely manner.
The scientists/managers in these allied EBIS CROs are
seasoned professionals who have accumulative knowledge
and experience in the identified area/segment. They can
perform not only as responsible project managers, but can
also serve as program advisors, with skillful hands and
intelligent minds. This “ace team” makes missions possible
and can overcome obstacles and avoid detours.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. [11] (PL)
was cofounded by the authors eyeing this paradigm shift and
unique position in the chain of translational medicine. Dedi-
cated disease modeling in preclinical conditions of Bone/
Figure 2 Expertise-Based Integrated Services (EBIS) concept. The integrated services are performed by a group of small contract
research organizations (CROs), each with its own specialties and profound experience and knowledge. The model is a one-stop shop
wherein any member of the chain can be the lead contact for the full package services.
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becomes one integrally driven part of the EBIS on pharma-
cology. The installation of an electronic database (IDBS,
Guildford,UK) was the first in China; it is used for preclinical
experiments at PL and eases concerns over quality and in-
tellectual property. Functional video streaming at PL reduces
the distance and spatial issues for its global clientele. The
quick renovation of the facility to house a large amount of
human disease-related animal models proves the company’s
flexibility and its determination to put the clients’ needs first.
Tight quality assurance operations ensure that the deliver-
ables meet global regulatory requirements. Open communi-
cation and task-oriented teams among the multifunctional
cross-trained staff accelerate the conversion from study
design to reporting. The operational outcomes have been
brilliant, with multiple filings to the Food and Drug Adminis-
tration and the China Food and Drug Administration (CFDA)
and passed audits.
New paradigm
The dust storm produced by M&As continues rolling through
the medical industries. The wealth of knowledge and ex-
periences gained in CROs have made them indispensable
and able to adapt to engage their own R&D. Although this
appears to be a conflict of interest and possibly mutually
exclusive, individual successful cases are emerging. This is
because of the depth and the infinite inventions of the
human mind at the beginning of the chain of translational
medicine. Each inventor’s organization has established a
group that constantly scouts for new technology to broaden
the pipeline, to decode the disease’s pivotal mechanism,
and to shorten the development time. In addition, the
creativity of the human brain makes the routes to suc-
cessful marketing on the other end of the chain of trans-
lational medicine so versatile that not one recipe is
identical to another. Therefore, finding the match for M&As
may be a new business model.
New types of CROs are arising. The functions of these
CROs are to assist disease diagnosis by various biomarkers, to
visualize the progression of the diseasewith advanced image
analysis technology, to formulate the deliverables by maxi-
mizing the intended therapy, to target the specific/vulner-
able subpopulation by meta-analysis and epidemiology, and
to treat patients with a personalized care system. CROs,swiftly evolving in accordance with market needs, have
become the essential vehicle to deliver translational medi-
cine [12]. The main recipients of the most beneficial results
from this new paradigm are the patients.
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